Translational stroke research is at a turning point. Of countless efficacious interventions reported in animal models of stroke, few if any have proven unequivocally efficacious in clinical trials, and none has entered clinical practice since thrombolysis [1] . Despite the widened therapeutic windows for systemic and endovascular thrombolysis, more than 90 % of acute stroke victims do not benefit from therapeutic options directly limiting the ischemic injury and improving the functional outcome [2] . Therefore, the translational roadblock is still standing [3] . As we explore the reasons for failure and consider novel strategies to enhance the predictability and clinical relevance of preclinical stroke research, we must be prepared to challenge the scientific methodology and even the most fundamental concepts in stroke pathophysiology. This special edition collects papers from renowned experts in the field on topics that are likely to shape the next generation of translational stroke research.
Over the recent years, stroke research has seen fundamental methodological improvements [4] . The concept of ultrastandardized stroke modeling is challenged by the inherent variability of stroke in patients, increasingly considered an essential element of human condition. Kent and Mandava suggest an entirely new approach to stroke modeling by considering stroke severity and other baseline factors on outcome, and embrace variability. They utilize statistical methods developed for clinical investigations to strengthen the translational power of their approach [5] . Ergul et al. emphasize the importance of modeling prevalent stroke comorbidities, hypertension and diabetes, when considering stroke complexity [6] while Ahnstedt and co-workers provide a strong rationale for investigating sex differences in translational stroke research [7, 8] . Hoffmann et al. describe confounding effects of anesthesia in general, and the specific impact of different anesthetics on stroke outcome [9] . Yet, implementing all relevant factors can hardly be achieved by a single center and will result in inter-study heterogeneities most likely prohibiting clear statistical results with common sample sizes. The research community is examining and debating concepts derived from clinical research such as the new preclinical Bphase 3^trial platforms to meet these challenges [10, 11] . Boltze et al. summarize the community opinion on multicenter (Bphase 3^) preclinical trials, a new concept for confirmative stroke research [12] . Last but not the least, we need to redefine the academic-industry collaborations in translational stroke research, which are sometimes impeded by simplistic research strategies or by focusing on improper readout parameters [13] . Those may initially limit study costs, but can lead to falsenegative results.
Intelligent endpoint selection is another key element in planning experimental as well as clinical studies. Functional endpoints are considered indispensible in preclinical stroke research, but do not necessarily predict clinical outcomes [14] . The issue is even more pressing in stroke recovery research where tissue endpoints are scarce. The correspondence between clinical and preclinical functional outcomes must hence be examined and enhanced. New concepts on how recovery should be measured preclinically (e.g., by a tailored latent variable approach) are suggested by Hommel et al. [15] while Jolkkonen and Kwakkel suggest to tackle confounders and sources of study result variability [16] . Muir and Macrae show that multimodal neuroimaging as a clinically relevant outcome surrogate can improve accuracy and statistical power in smaller samples and is a meaningful preclinical trial recruitment tool [17] . It further enables repeated longitudinal assessments of brain structure, perfusion, and metabolism, representing best-correlating endpoints to neurological function.
The relevance of the central nervous and the immune Bsuper^systems' interplay in stroke pathophysiology and outcome is increasingly recognized [18] . It provides novel targets for therapeutic interventions. For instance, the interleukin-1 receptor antagonist (IL-1RA), already applied in clinical rheumatology, is of direct relevance for research programs targeting human stroke by means of immunomodulation.
McCann and colleagues assessed preclinical study quality and reported outcomes. Their analyses clearly support the IL-1RA treatment concept for stroke. They note that the quality of preclinical experiments has significantly increased as compared to previous research programs [19] . Dr. Becker describes inter-strain and inter-species differences in immune responses to stroke among frequently used animal models [20] . Liesz and Kleinschnitz review the role of regulatory T cells (T regs ) on the secondary inflammatory response after stroke, as well as different T reg sites of action such as the neurovascular unit and the surrounding inflammatory milieu [21] . Closely related, new and better experimental models of vascular cognitive impairment are needed as pointed out by Yang et al. [22] . Immune responses may play a substantial role [23] .
Cell-based therapies are at the cutting edge of experimental stroke treatment, currently being translated in early stage clinical studies [24] . Autologous transplantation of adult cell populations such as bone marrow mononuclear cells (BM MNC) is most frequently applied. The group of Dr. Savitz investigated the therapeutic impact of BM MNC subfractions after stroke, bringing clarity into the therapeutic mode of action [25] . Rodríguez-Frutos and colleagues point out that successful clinical implementation of cell therapies hinges on several factors, including safe and efficacious routes for cell administration [26] .
Although advances in mechanical recanalization have recently ended two decades of drought in stroke therapy development [27] , still only a small fraction of stroke victims benefit from it. The next natural step is to develop strategies that widen the therapeutic window for recanalization therapies as shown by Henninger and Fisher [2] . Linfante and Cipolla suggest combination therapies taking advantage of endovas cular thrombolysis [28] in order to include more patients. At the same time, new concepts overcoming existing contraindications must be developed.
While all topics discussed in this special issue are specifically relevant for stroke, many are also of general translational importance for the entire field of experimental neuroscience. By providing new ideas on current challenges and controversies, the contributions, concepts, and considerations herein ultimately aim to help overcome the translational roadblock.
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